These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25900274)

  • 41. Radioactive iodine: An unappreciated threat to salivary gland function.
    Sunavala-Dossabhoy G
    Oral Dis; 2018 Mar; 24(1-2):198-201. PubMed ID: 29480611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Preliminary report].
    Macioszek A; Baczyk M; Kopeć T; Sowiński J
    Endokrynol Pol; 2008; 59(5):403-10. PubMed ID: 18979451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
    Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
    J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan.
    Chen SC; Liu CJ; Hu YW; Yeh CM; Hu LY; Wang YP; Hung YP; Tzeng CH; Chiou TJ; Chen TJ; Teng CJ
    Gastric Cancer; 2016 Apr; 19(2):490-497. PubMed ID: 25772342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of Second Primary Malignancies After External Beam Radiotherapy for Thyroid Cancer.
    Jin MC; Qian ZJ; Megwalu UC
    Anticancer Res; 2022 Mar; 42(3):1359-1365. PubMed ID: 35220228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
    Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
    J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea.
    Cho YY; Lim J; Oh CM; Ryu J; Jung KW; Chung JH; Won YJ; Kim SW
    Cancer; 2015 Jan; 121(2):259-68. PubMed ID: 25223713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
    Gandhi S; Abhyankar A; Basu S
    Nucl Med Commun; 2014 Feb; 35(2):205-9. PubMed ID: 24217429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
    Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M
    Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Salivary gland function after sialendoscopy for treatment of chronic radioiodine-induced sialadenitis.
    Kim YM; Choi JS; Hong SB; Hyun IY; Lim JY
    Head Neck; 2016 Jan; 38(1):51-8. PubMed ID: 24995941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroid function and mortality in patients treated for hyperthyroidism.
    Franklyn JA; Sheppard MC; Maisonneuve P
    JAMA; 2005 Jul; 294(1):71-80. PubMed ID: 15998893
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.
    Kim S; Bang JI; Boo D; Kim B; Choi IY; Ko S; Yoo IR; Kim K; Kim J; Joo Y; Ryoo HG; Paeng JC; Park JM; Jang W; Kim B; Chung Y; Yang D; Yoo S; Lee HY
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3547-3556. PubMed ID: 35362796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
    Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
    J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?
    Cappagli V; Caldarella A; Manneschi G; Piaggi P; Bottici V; Agate L; Molinaro E; Bianchi F; Elisei R
    Int J Cancer; 2020 Nov; 147(10):2838-2846. PubMed ID: 32449158
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer.
    Verkooijen RB; Smit JW; Romijn JA; Stokkel MP
    Eur J Endocrinol; 2006 Dec; 155(6):801-6. PubMed ID: 17132748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thyroid Patient Salivary Radioiodine Transit and Dysfunction Assessment Using Chewing Gums.
    Okkalides D
    Cancer Biother Radiopharm; 2016 Nov; 31(9):330-341. PubMed ID: 27831763
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer.
    Ahn HY; Min HS; Yeo Y; Ma SH; Hwang Y; An JH; Choi HS; Keam B; Im SA; Park DJ; Park IA; Noh DY; Youn YK; Chung JK; Cho BY; Park SK; Park YJ
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3486-93. PubMed ID: 26147607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidemiology and treatment of lacrimal gland tumors: a population-based cohort analysis.
    Mallen-St Clair J; Arshi A; Tajudeen B; Abemayor E; St John M
    JAMA Otolaryngol Head Neck Surg; 2014 Dec; 140(12):1110-6. PubMed ID: 25393577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.